Diseases of the Colon & Rectum

Skip Navigation LinksHome > May 2008 - Volume 51 - Issue 5 > Identification of Patients with High-Risk Stage II Colon Can...
Diseases of the Colon & Rectum:
doi: 10.1007/s10350-008-9246-z
Original Contribution: PDF Only

Identification of Patients with High-Risk Stage II Colon Cancer for Adjuvant Therapy.

Quah, Hak-Mien M.D.; Chou, Joanne F. M.P.H.; Gonen, Mithat Ph.D.; Shia, Jinru M.D.; Schrag, Deborah M.D.; Landmann, Ron G. M.D.; Guillem, José G. M.D.; Paty, Philip B. M.D.; Temple, Larissa K. M.D.; Wong, W. Douglas M.D.; Weiser, Martin R. M.D.

Collapse Box


Purpose: Adjuvant therapy for Stage II colon cancer remains controversial but may be considered for patients with high-risk features. The purpose of this study was to assess the prognostic significance of commonly reported clinicopathologic features of Stage II colon cancer to identify high-risk patients.

Methods: We analyzed a prospectively maintained database of patients with colon cancer who underwent surgical treatment from 1990 to 2001 at a single specialty center. We identified 448 patients with Stage II colon cancer who had been treated by curative resection alone, without postoperative chemotherapy.

Results: With median follow-up of 53 months, 5-year disease-specific survival for this cohort was 91 percent. Univariate and multivariate analyses identified three independent features that significantly affected disease-specific survival: tumor Stage T4 (hazard ratio (HR), 2.7; 95 percent confidence interval (CI), 1.1-6.2; P = 0.02), preoperative carcinoembryonic antigen >5 ng/ml (HR, 2.1; 95 percent CI, 1.1-4.1; P = 0.02), and presence of lymphovascular or perineural invasion (HR, 2.1; 95 percent CI, 1-4.4; P = 0.04). Five-year disease-specific survival for patients without any of the above poor prognostic features was 95 percent; five-year disease-specific survival for patients with one of these poor prognostic features was 85 percent; and five-year disease-specific survival for patients with >=2 poor prognostic features was 57 percent.

Conclusions: Patients with Stage II colon cancer generally have an excellent prognosis. However, the presence of multiple adverse prognostic factors identifies a high-risk subgroup. Use of commonly reported clinicopathologic features accurately stratifies Stage II colon cancer by disease-specific survival. Those identified as high-risk patients can be considered for adjuvant chemotherapy and/or enrollment in investigational trials.

(C) The ASCRS 2008


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.